异动解读|Viking Therapeutics盘中下跌8.1%,市场消化三季度亏损超预期

行情直击
Nov 05

11月5日,Viking Therapeutics盘中下跌8.1%,报25.705美元/股,成交额2966.85万美元。

本次异动可对应的公开消息面,主要是公司近日披露的三季度业绩中亏损幅度高于市场预期。数据显示,公司第三季度每股亏损1.55美元,高于市场预期的亏损1.06美元至1.07美元。

不过,公司同期亦披露了积极研究进展,并称现金余额约9.6亿美元,显示其在推进肥胖症药物VK2735临床开发方面仍具资金基础。当前股价回落,反映市场对盈利压力的消化仍占上风。

Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司,致力于开发新的,第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10